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A B S T R A C T
Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease characterised by the pro-
duction of pathogenic autoantibodies against nuclear self-antigens. The anti-inflammatory and tolerogenic cy-
tokine Interleukin-10 appears to play a paradoxical pathogenic role in SLE and is therefore currently ther-
apeutically targeted in clinical trials. It is generally assumed that the pathogenic effect of IL-10 in SLE is due to
its growth and differentiation factor activity on autoreactive B-cells, but effects on other cells might also play a
role. To date, a unique cellular source of pathogenic IL-10 in SLE has not been identified. In this review, we focus
on the contribution of different CD4+T-cell subsets to IL-10 and autoantibody production in SLE. In particular,
we discuss that IL-10 produced by different subsets of adaptive regulatory T-cells, follicular helper T-cells and
extra-follicular B-helper T-cells is likely to have different effects on autoreactive B-cell responses. A better un-
derstanding of the role of IL-10 in B-cell responses and lupus would allow to identify the most promising
therapies for individual SLE patients in the future.
1. Systemic lupus erythematosus: a highly heterogeneous disease
characterized by the production of autoantibodies to nuclear self-
antigens
Systemic lupus erythematosus (SLE) is a prototypical multi-organ
autoimmune disease, whose etiology is still unknown [1]. For the
biology of IL-10 SLE is of particular interest, because it is generally
assumed that IL-10 paradoxically plays a pathogenic role, and IL-10
neutralization may become a future therapeutic strategy [2]. Like many
autoimmune diseases, SLE is a multi-factorial disease where both ge-
netic and environmental factors contribute to the individual disease risk
[1]. Genome-wide association studies have identified several risk loci,
which have significantly contributed to our current understanding of
lupus pathogenesis [3]. Among the identified genetic risk factors MHC/
HLA haplotypes show by far the strongest association, suggesting a key
role for CD4+T-cells that recognise peptides presented on MHC class II
complexes. Other genetic polymorphisms that suggest an involvement
of T-cells and are shared with other autoimmune diseases are PTPN22,
a tyrosine phosphatase inhibiting T cell receptor signalling, and STAT4,
a transcription factor that promotes IFN-γ production [4]. SLE is
characterised by the breakdown of B cell tolerance and the production
of autoantibodies, in particular against nuclear self-antigens. Although
these antibodies can develop long before disease onset, they are be-
lieved to play a pathogenic role and are produced by autoreactive
plasmablasts or plasma cells. They are mainly of the IgG class and are
often somatically hyper-mutated, consistent with a role of CD4 help in
their generation [5]. In addition, some polymorphisms in loci involved
in B-cell activation, like BLK or BANK1, are also associated with SLE
risk, suggesting also a role for intrinsic B cell hyper-activity. Consistent
with a pathogenic role of B-cells in SLE, antibodies selectively targeting
the B cell compartment (i.e. belimumab (anti-BAFF) and rituximab
(anti-CD20)) provide therapeutic benefit [6–8] (Fig. 1).
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In addition to an increased activation of autoreactive B-cells by
autoreactive T-cells, the genetic association studies also point to an
important role of innate immunity in SLE [9]. In particular, the asso-
ciation of loci coding for Integrin αM and Fcγ receptors with SLE sug-
gests a role for inefficient phagocytosis and clearing of immune com-
plexes. Notably, the association with Integrin αM is apparently unique
for SLE [4]. Also genetic deficiencies in the classical complement
pathway, which are strongly associated with the risk of SLE, are
thought to decrease the clearance of apoptotic cell debris and immune
complexes, resulting in increased availability of nuclear self-antigens
[9]. Finally, several loci coding for Interferon regulatory factors are
associated with disease risk and SLE is characterised by an IFN
signature in peripheral blood mononuclear cells. Immune complexes
formed by autoantibodies and ribonucleoproteins activate plasmacytoid
DC and induce type 1 IFN production, which acts in turn as a natural
adjuvants to boost T- and B-cell responses [10]. Indeed, neutralization
of type 1 interferon has therapeutic potential to treat SLE [11] (Fig. 1).
In addition, immune complexes can deposit in the kidney and induce
severe organ damage [12]. Taken together, the genetic risk factors are
consistent with a scenario where inefficient clearing of material from
dead cells leads to the activation of autoreactive T-cells, and conse-
quently also of autoreactive B-cells that differentiate to autoreactive
plasma blasts and secrete potentially pathogenic autoantibodies. These
autoantibodies can form immune-complexes with their target antigens,
Fig. 1. Mechanisms that contribute to the pathogenesis of systemic lupus erythematosus (SLE) and their targeting by therapeutic antibodies. SLE is
characterized by a break-down of B-cell tolerance to nuclear self-antigens and the generation of potentially pathogenic autoantibodies. Presumably due to an
inefficient clearing of nuclear material from dead cells by phagocytes, nuclear self-antigens are presented in a non-tolerogenic manner to autoreactive helper T-cells
that in turn could activate autoreactive B-cells to differentiate antibody-producing plasma cells. Autoantibodies specific for nuclear acids can form immune com-
plexes that induces type 1 IFN from pDC via TLR7/9, BAFF production from myeloid cells and can directly induce kidney damage. Type 1 IFN acts as a natural
adjuvants, while BAFF stimulates selectively B-cells. Both pathways can be blocked with therapeutic antibodies. Moreover, B-cells can be therapeutically depleted
with anti-CD20 antibodies.
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and in the case of antibodies against nuclear antigens like double-
stranded (ds) DNA induce a type 1 IFN response that further enhances
the activation of autoreactive lymphocytes. In addition, cells of the
innate immune system like macrophages can be activated by immune
complexes and boost autoantibody production by secreting soluble B-
cell stimulating factors like BAFF (Fig. 1).
While these mechanisms provide a plausible explanation for the
systemic disease manifestations that may at least in part be mediated
via autoantibody production and immune complex formation, it should
be noted that SLE is a highly heterogeneous disease [13] that can affect
different organs, like the skin, the joints, the CNS, the haematological
compartment or the kidneys. Interestingly, the intestine is rarely af-
fected in SLE, in spite of the fact that it is in general a highly sensitive
organ to immune dysregulation. Nevertheless, the intestinal micro-
biome may play a critical role in SLE [14].
2. The evidence for a pathogenic role of IL-10 in SLE
The study of IL-10/IL-10R-deficient mice and humans has revealed
that the non-redundant function of IL-10 signalling in humans and mice
is to inhibit excessive inflammation in the gut in response to the in-
testinal microflora [2]. Also in organ-specific autoimmune diseases IL-
10 is thought to be protective [15], since it inhibits pathogenic in-
flammation and promotes self-tolerance. The notion that IL-10 plays a
pathogenic role in SLE seems therefore paradoxical. However, besides
its anti-inflammatory properties, IL-10 also acts as a growth and dif-
ferentiation factor on cytotoxic lymphocytes [16] and B-cells [17], and
promotes survival of autoreactive B-cells from germinal centres in vitro
[18]. Notably, however, vaccination-induced IgG responses are normal
in IL-10-deficient mice [19], suggesting that other STAT3-activating
cytokines like IL-21 can substitute for IL-10 to induce differentiation of
naïve B-cells to plasma cells, which has indeed been demonstrated in
vitro [20–22].
Treatment of mice with anti-IL-10 antibodies provided insight into
the role of IL-10 in autoreactive B-cell responses in vivo, as CD5+
B1cells that can secrete T-independent, poly-specific and self-reactive
“natural” IgM antibodies were killed upon anti-IL-10 treatment, while
conventional B2-cells were spared [23]. However, it was later realised
that the high affinity anti-dsDNA IgG autoantibodies that play a pa-
thogenic role in SLE are produced predominantly by conventional B2-
cells [24]. Nevertheless, the same group also showed that treatment of
lupus-prone NZB/W F1 mice with anti-IL-10 antibodies reduced serum
levels of anti-dsDNA IgG autoantibodies and strongly increased sur-
vival, while administration of IL-10 accelerated autoimmunity [25].
The protective effect of IL-10 neutralization was mediated by increased
TNF-α levels in this spontaneous model of lupus nephritis, but how
increased TNF-α protected from disease was not addressed in this study.
Of note, therapeutic TNF neutralization in patients can lead to auto-
antibody production and anti-TNF-induced lupus [26], suggesting that
TNF plays a role in controlling autoreactive B-cell responses both in
humans and mice. Interestingly, TNF can selectively kill auto-reactive
CD8+T-cells from various autoimmune patients, including those with
lupus [27], but whether TNF could also kill autoreactive helper T-cells
or B-cells from SLE patients remained unclear. Unfortunately, the role
of IL-10 in murine lupus models is highly variable [28]. Thus, in the
MRL/lpr lupus model, where autoreactive lymphocytes expand due to
impaired Fas-dependent killing, IL-10 is protective, since it inhibited
pathogenic Th1 responses [29]. Patients with genetic defects in the Fas
pathway develop however an autoimmune lymphoproliferative syn-
drome [30] which has largely distinct clinical features as compared to
SLE. Nevertheless, given the huge heterogeneity of SLE [13], it is pos-
sible that the role of IL-10 in SLE patients also depends on clinical
characteristics, like the involvement of different organs.
In SLE patients several lines of evidence point to a pathogenic role
of IL-10. It is well documented that IL-10 serum levels are increased in
SLE, at least in a proportion of patients [28]. Moreover, several groups
found an association of IL-10 serum levels with disease activity scores
[28,31]. Interestingly, a fraction of SLE patients produces auto-
antibodies against IL-10 [32], but if these anti-IL-10 antibodies were
neutralizing was not investigated. IL-10 production is influenced by
polymorphisms in regulatory elements of the IL-10 gene, and a large
body of literature reports associations of single nucleotid polymorph-
isms (SNP) in the IL-10 gene and SLE risk [33–35]. Many independent
studies found a significant association with SLE, although the odd’s
ratios were in general rather low, but this is not unusual for multi-
factorial diseases. Notably, the association with the most studied SNPs
at position -1082/-819/-592 was not confirmed in all analysed patient
cohorts [33]. A whole genome methylation analysis revealed that hypo-
methylation of the IL-10 promoter, which indicates increased accessi-
bility for transcription (see Review by Kuchroo and colleagues in this
special issue), was specifically associated with SLE, in particular in
patients with higher disease activity [36]. In addition, immune cells
from the peripheral blood of SLE patients spontaneously produce IL-10
[37], and the ratio of IL-10 to IFN-γ production was reported to cor-
relate with disease activity [38]. Intriguingly, B cells from SLE patients
can spontaneously produce antibodies, and IL-10 was shown to be
critical for this spontaneous antibody production in vitro, as well as for
autoantibody production in humanised mice in vivo [39]. Moreover,
anti-IL-10 treatment resulted in reduced human IgG levels in SCID mice
implanted with hybridomas secreting anti-dsDNA antibodies [40].
These findings suggested that increased IL-10 production in SLE is not
an epiphenomenon, reflecting merely a disease-associated hyperactivity
of immune cells, but that IL-10 is part of a pathogenic mechanism that
contributes to the disease. Consistently, Llorente et al. reported on 6
active SLE patients that were treated with a murine anti-IL-10 antibody
[41]. Strikingly, although the patients, as expected, mounted an im-
mune response to the mouse antibodies, they responded well to the
treatment: joint and cutaneous involvement improved, corticosteroid
dosage could be reduced and 5 patients had inactive disease after 6
months. Surprisingly, anti-dsDNA autoantibodies only decreased in one
patient upon anti-IL-10 treatment [41]. Nevertheless, these results were
sufficiently promising to motivate a randomised, multi-centred and
placebo-controlled Phase II clinical trial with a higher number of SLE
patients with a humanized monoclonal anti-IL-10 antibody (clinical-
trials.gov/ct2/show/NCT02554019). This antibody showed a favour-
able safety and tolerability profile, but the clinical efficacy has not been
reported yet. The results of this trial will undoubtedly lead to a better
understanding of the role of IL-10 in SLE.
3. Are B cells the only relevant targets of IL-10 in SLE?
Conditional IL-10R-deficient mice illustrated that the target cells of
IL-10 in colitis were mainly intestinal macrophages [42], and poten-
tially also Th17-cells [43]. Conversely, given the well-established pa-
thogenic role of autoantibodies and immune complexes in SLE, it is
generally assumed that IL-10R signalling in B cells and/or plasmablasts
is key to its pathogenic effects. This notion is consistent with the ca-
pacity of IL-10 to induce survival, proliferation and differentiation of B-
cells in vitro [44]. However, whether IL-10R signalling is required ex-
clusively in the B-cell compartment in vivo has not been demonstrated
yet. For T-cell dependent antibody production we observed that the role
of IL-10R signalling in B-cells varied surprisingly according to the T-cell
population that provided help [45]. In addition, it is still possible that
also other cellular targets of IL-10 are important for SLE pathogenesis.
Indeed, the rather surprising finding that anti-IL-10 antibody treatment
in SLE rapidly reduced cutaneous manifestations in patients that
maintained high levels of autoantibodies [41], suggests that IL-10
might play a pro-inflammatory role in tissues independently of its ef-
fects on B-cells. Notably, also CD8+ T-cells can be stimulated by IL-10
[46–48](see review in this special issue by M. Oft), and they might play
a pathogenic role in SLE as well [49–51]. Conversely, IL-10 has potent
inhibitory effects on monocytes and dendritic cells (DC) [52], but this
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inhibitory function seems to be intact in SLE [53,54]. DC and macro-
phages could also be differentially affected by IL-10 [55,56], but if this
interesting aspect is relevant for SLE is currently unknown.
IL-10 is involved in wound healing. IL-10R1 expression is pre-
dominantly expressed on immune cells [52], and this function could
thus be mediated through the modulation of pro-inflammatory and fi-
brinogenic cytokines by immune cells. Nevertheless, several studies
provided evidence for a direct effect of IL-10 on non-immune cells like
fibroblasts, including IL-10R1 expression and IL-10-dependent signal-
ling in these cells [57]. It should however be noted that a reported
direct effect of IL-10 on keratinocytes [58], could not be confirmed by
others [59]. Nevertheless, IL-10R1 expression was also detected on
intestinal epithelial cells [60], consistent with the notion that IL-10
signalling is also relevant in non-immune cells. Studies with IL-10R
reporter mice and cell-type specific knock-down of IL-10R signalling of
IL-10-dependent lupus models may clarify this issue.
In summary, although the paradoxical notion that IL-10 plays a
pathogenic role in SLE is increasingly recognised, the cellular targets
remain to be defined, and the proposed mechanism, i.e. the induction of
autoantibodies, might not explain all pathogenic effects in target tis-
sues.
4. Multiple cellular sources contribute to IL-10 production in SLE
IL-10 is produced by most types of leukocytes [52] and in order to
understand the mechanisms by which IL-10 promotes SLE it is thus
important to identify the relevant cellular sources. In cell lineage-spe-
cific IL-10 k.o. mice, T-cells, but not macrophages or B-cells, were found
to be the relevant source of IL-10 to prevent spontaneous colitis
[42,61]. Conversely, a unique cellular source of pathogenic IL-10 in
lupus has not been identified, also because, as discussed above, the role
of IL-10 in murine lupus critically depends on the model that is em-
ployed. Studies on polymorphisms of the IL-10 locus that are associated
with SLE in humans contributed to the identification of potentially in-
volved signalling pathways, but did not point to a unique cellular
source. Thus, the associations of SNPs in the IL-10 gene with IL-10
production was analysed by several groups, and many of them were
shown to alter transcription factor binding to the IL-10 promoter [62].
IL-10 production varied according to SNPs at position 1082/-819/-592
upon LPS stimulation of total leukocytes and in EBV-transformed B-
cells, indicating that these polymorphisms impact on IL-10 production
by myeloid and B cells [62]. The GG genotype of the -1082 SNP was for
instance shown to increase the binding of the Sp1 transcription factor
and consequently of IL-10 production in LPS-stimulated B-cell lines
[63]. Phagocytes produce IL-10 in response to dying cells [64], and in
individuals with the SLE risk haplotype macrophages exposed to
apoptotic cells displayed increased transcriptional activity of the IL-10
gene [65]. Another SNP 1kB downstream of IL-10 was shown to be
associated with SLE risk in a very large patient cohort, and IL-10 pro-
duction from this site was shown to be mediated by the transcription
factor Elk-1. However, this pathway was again active in several dif-
ferent immune cell subsets, including monocytes, B-cells and T-cells
[35]. Studies on the associations of polymorphisms with IL-10 levels
produced by polyclonal T-cells [66] are complicated by the fact that the
individual antigen exposure is expected to have a strong impact on T-
cell IL-10 production [67].
The analysis of IL-10 production by different leukocyte subsets did
also not lead to the identification of a unique cellular source of IL-10.
The spontaneous IL-10 production of peripheral blood mononuclear
cells from SLE patients was shown to be mainly due to monocytes and
B-cells [37], with a variable contribution of T-cells [68]. Notably, im-
mune complexes induce not only production of pathogenic type 1 IFN
from pDC [11], but also IL-10 from monocytes/macrophages via FCRγII
[69,70]. Therefore, it seems likely that this pathway contributes sig-
nificantly to the increased serum levels of IL-10, in particular in patients
with high disease activity. Moreover, IFN-α in serum from SLE patients
instructed monocytes to promote B-cell IgG production, and this B
helper effect was dependent on IL-10 and BAFF [71]. IL-10 is also
produced by DC, and IL-10 production by DC was found to be dysre-
gulated in murine lupus caused by enhanced IRF4 activity [72]. In the
human DC compartment, IL-10 is selectively produced by CD1c+DC
(cDC2) and has a unique regulation [48], but if cDC2 have altered IL-10
production in SLE has not yet been investigated. Finally, IL-10 pro-
duction by B-cells might promote plasma blast differentiation in an
autocrine feed-forward loop [73]. However, IL-10 in the B-cell com-
partment is also produced by regulatory B-cells (see review by Filla-
treau and colleagues in this special issue) that potentially have a pro-
tective role, but are functionally impaired in SLE [74–76].
In summary, the current evidence suggests that multiple cellular
sources contribute to the excessive IL-10 production in lupus, including
myeloid cells, B-cells and also T-cells. We will focus on the role of
different CD4+T-cell subsets for the remainder of this review.
5. IL-10 producing regulatory and helper T-cell subsets
In the T-cell compartment, α/βTCR+CD4+T-cells produce the
highest levels of IL-10. In the CD4+ T-cell compartment, IL-10 is pro-
duced at particular high levels by regulatory T-cells, which in most but
not all cases inhibit or skew B-cell responses [77–81]. IL-10 is however
also produced by non-regulatory T-cells which might promote in-
flammation (see Review by Huber&Gagliani and colleagues in this
special issue), in particular in the spleen [82]. T helper cells are highly
abundant and some possess B helper capabilities [83–87]. All human T
helper subsets can produce IL-10 [88–90] and could thus make an
important contribution to total IL-10 production, in particular upon
cognate interaction with auto-reactive B-cells. Interestingly, besides
CD4+T-cells also CD4−CD8− α/βTCR+T-cells have been shown to
spontaneously induce anti-dsDNA autoantibody production from auto-
logous B-cells in SLE patients [91]. However, if IL-10 was produced by
these unconventional autoreactive T-cells and if IL-10 promoted auto-
antibody generation was not investigated.
5.1. IL-10 producing regulatory T-cells suppress B-cell responses, but are
dysfunctional in SLE
The best-defined regulatory T-cells express the lineage-defining
transcription factor FOXP3 [92], and FOXP3+Tregs can produce high
levels of IL-10 in humans and mice, in particular in the mucosa and in
the skin [79,93–96]. FOXP3 is quite selectively expressed in Tregs, and
genetic deficiencies in its gene causes multi-organ autoimmune mani-
festations and autoantibody production both in humans and mice, in-
dicating that FOXP3+Tregs are required to maintain self-tolerance and
to suppress autoreactive B cells [97,98]. Consistently, FOXP3+Tregs
suppress B-cell responses, and specialised B suppressor Tregs (Tfr) are
present in germinal centres of secondary lymphoid organs [99].
Therefore, a defect in FOXP3+Tregs was expected to contribute to SLE
pathogenesis, but contradictory results were published on the numbers
and functionalities of Tregs in SLE [100]. Notably, patients that have
only a partial defect in FOXP3 expression also develop anti-enterocyte
autoantibodies and non-IPEX autoimmune enteropathy [101,102].
These findings indicate that FOXP3+Tregs are required to prevent au-
toimmunity in the small intestine, and that a defect in FOXP3+Tregs is
insufficient to induce lupus-like symptoms. It is thus possible that
regulatory T-cells that do not express FOXP3, but also suppress B-cell
responses, play an important role in lupus. Indeed, IL-10 is not only
produced by FOXP3+Tregs, but is the defining cytokine of the so-called
“type 1 regulatory” (Tr1) T-cells [103]. Cells that satisfy the broad
current definition of Tr1-cells, i.e. CD4+T-cells with IL-10 producing
capacities and suppressive functions that are distinct from established
T-cell subsets [104], can be generated in humans with different pro-
tocols in vitro. Unexpectedly, Tr1-cells that were generated upon TCR
activation and co-stimulation via the complement receptor CD46 were
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shown to promote B-cell responses [77]. How in vitro generated Tr1
cells are related to in vivo occurring Tr1-cells is however difficult to
address, in particular in complex human diseases like SLE [105]. In
inflamed human tonsils, the most accessible secondary lymphoid organ
to study human B-cell responses, Tr1-cells that produce high amounts of
IL-10 ex vivo could be identified [79,106]. Importantly, tonsillar Tr1-
cells and Tregs inhibited B-cell responses, but this suppression was in-
dependent of IL-10 production. Similar findings were reported in-
dependently for tonsillar Tr1-cells identified according to expression of
either Lag3 or CCR5/PD1 [79,106]. This is not just a trivial confirma-
tion, since CCR5+PD1+ and Lag3+ Tr1-cells differ in the expression
levels of surface Lag3 and IL-7R, as well as the putative lineage-defining
transcription factor Eomes [107], and there is consequently little
overlap between these two Tr1-cell population in human blood
[93,108]. Importantly, in marked contrast to CD4+IL-7R+ T-cells, both
Foxp3+Tregs and Eomes+Tr1-cells are largely unable to up-regulate
CD40 L expression [79,108,109]. This defect has major implications for
the regulation of B-cell responses, since humans and mice with genetic
defects in the CD40/CD40 L pathway have impaired IgG induction
[110,111]. Conversely, the absence of the most potent B helper cyto-
kine IL-21 results only in a partial reduction of IgG production [112].
Interestingly, provision of exogenous CD40 L was sufficient to induce B-
cell IgG production in the presence of Tr1-cells, but not of
FOXP3+Tregs [79]. Thus, the lack of CD40 L in Eomes+Tr1-cells is
mandatory for their capabilities to suppress B-cell responses. Moreover,
the presence of CD40 L is sufficient to convey B helper functions to Tr1-
cells, presumably because -unlike FOXP3+Tregs- Tr1-cells secrete high
levels of IL-21. In SLE patients, Eomes+Tr1-cells were found to be in-
creased but dysfunctional, since they were unable to suppress B-cell IgG
production [79]. Conversely, Lag3+Tr1-cells are controlled by the
transcription factor Egr-2 [113, 114], suppressed B-cell responses via
cell-cell contact and TGF-β3, and were reduced in SLE patients
[80,115]. Eomes+Tr1-cells even provided B-cell help in some patients,
most likely due to residual CD40 L expression. In contrast,
FOXP3+Tregs from the same patients suppressed IgG production effi-
ciently, indicating that the defect was Tr1-specific [79]. Notably, Th1
effector memory cells contain a fraction of Eomes+T-cells that share
some key characteristics with Eomes+Tr1-cells, but unlike Tr1-cells
they express IL-7R and CD40 L, and they produce only low levels of IL-
10 [108]. These Eomes+Th1-cells may represent pre-cursors of Eo-
mes+Tr1-cells, and based on this hypothesis it seems plausible that
Eomes+Th1-cells fail to efficiently down-regulate CD40 L upon differ-
entiation to Tr1 effector cells in SLE patients. Since IL-27 down-regu-
lated CD40 L in synergy with Eomes [108], it seems plausible that IL-
27-dependent Tr1-cell generation is disturbed in SLE. Indeed, a role for
IL-27 in lupus has been proposed [116–118]. Alternatively, the defect
might be related to dysfunctional Bregs that fail to induce Tr1-cells in
SLE [75,119], but whether Breg-induced Tr1-cells express Eomes and/
or require IL-27 remains to be addressed.
Overall, these studies suggest that dysfunctional IL-10 producing
regulatory B and T lymphocytes are key to SLE pathogenesis (Fig. 2).
5.2. Follicular helper T-cells are activated in lupus and contribute to
autoantibody production
As stated above, IL-10 is also produced helper T-cells, which may
thus contribute to systemic IL-10 accumulation in SLE patients. It
should be noted that IL-10 has a peculiar regulation as compared to
other cytokines, since resting helper T-cells produce IL-10 preferentially
at late time points [79,120]. Consequently, brief polyclonal standard
stimulation is well suited to induce IL-10 production in activated and
regulatory T-cells, but not in quiescent helper T-cells that represent the
large majority of T-cells in human peripheral blood. A plausible tele-
ological explanation for the different kinetics of IL-10 production by
regulatory and helper T-cells is that rapid IL-10 production is required
to inhibit DC, macrophages and potentially also Th17 effector cells that
express high levels of IL-10R [43,121,122]. Conversely, late IL-10
production is tailored to promote B-cell and CTL responses, since naive
B-cells and CD8+T-cells first have to up-regulate IL-10R expression
upon activation. IL-10 was originally found to be produced by Th2-cells
[123], which could thus induce B-cell responses via IL-10 and IL-4.
Indeed, a shift to Th2-cells in SLE patients was originally reported
[124]. After the discovery of Th17-cells and of TFH-cells the original
conceptual Th1/Th2 framework has however been extensively revised.
It is now well established that TFH-cells are the professional B helper
effector T-cells and reside in germinal centres of secondary lymphoid
organs. They co-express CXCR5, ICOS, BCL6 and produce high levels of
IL-21 [125]. Interestingly, human TFH-cells produce some IL-4 [126],
and in immune responses against parasites murine TFH-cells are derived
from Th2-cells [127]. Given their potent B helper functions, TFH were
obvious candidates for the induction of pathogenic autoantibodies in
SLE [128]. Indeed, in the sanroque lupus mouse model TFH-cells are
required to induce anti-dsDNA autoantibodies [129]. Since it is difficult
to obtain lymphoid organ tissue samples of SLE patients, very little is
known about canonical TFH-cells in SLE. However, circulating
CXCR5+T-cells possess potent B helper capabilities and were proposed
to be derived from TFH effector cells [86,130]. Notably, however, cir-
culating CXCR5+T-cells are pre-dominantly non-polarised central
memory T-cells [131] and express only low levels of ICOS, IL-21 and
BCL6. A fraction of circulating CXCR5+T-cells express however PD1
and some BCL6, and thus appear to be more closely related to TFH-cells
that are found in germinal centres [130,132]. Indeed, in human SLE,
CXCR5+TFH cells display a more activated PD1+CCR7loTFH-like phe-
notype, and expansions of different CXCR5+T-cell populations was
reported in SLE patients [133–136]. The capacity of TFH-cells to induce
autoantibodies in SLE was however assessed in the presence of exo-
genous TCR agonists like anti-CD3/28 antibodies, and whether circu-
lating CXCR5+TFH-like cells are autoreactive and can productively in-
teract with autoreactive B-cells, a key point to understand their role in
SLE, is still unclear. In contrast to previous reports we observed overall
reduced frequencies of CXCR5+T-cells in SLE patients [45], but purified
CXCR5+TFH-like cells from SLE patients were able to spontaneously
induce IgG from autologous B-cells, suggesting that they may con-
tribute to autoantibody production. IL-10 produced by TFH-cells was
originally thought to reflect their B helper capabilities [90], but a recent
report showed that it actually inhibits B-cell responses in mice in vivo
[137]. We obtained very similar results with both tonsillar TFH-cells and
with circulating TFH-like subsets in humans [45]. Therefore, IL-10
production by TFH-cells, similar to IL-10 produced by regulatory T-cells,
might reflect disease activity, but is not necessarily playing a patho-
genic role (Fig. 2).
5.3. IL-10 producing extra-follicular helper T-cell subsets promote short-
lived autoantibody responses
Although TFH are the most potent B helper T-cells, also other CD4+T
cell populations can promote B-cell responses [83,87,138]. In parti-
cular, extra-follicular B helper T-cells have been identified in human
tonsils [139], and are drivers of autoantibody production in the MRL/
lpr lupus mouse model [140]. However, the involvement of TFH versus
extra-follicular B helper T-cells varies strongly in different mouse
models [129]. In the NZB/W model, where IL-10 plays a pathogenic
role, both long-lived and short-lived plasma blasts contributed to anti-
dsDNA IgG production [141]. Since short-lived plasma blasts can be
generated outside of germinal centres, this suggests a role for both TFH
and extra-follicular B helper T-cells. In SLE patients, the levels of pa-
thogenic anti-dsDNA autoantibodies are highly dynamic [142], and
rapidly drop in some patients upon Rituximab treatment [7]. Since
long-lived plasma cells are not targeted by Rituximab, these findings
suggest that anti-dsDNA autoantibodies in these patients were produced
predominantly by short-lived plasma blasts. Moreover, a fraction of IgG
autoantibodies is not somatically hyper-mutated [5], further suggesting
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a contribution of extra-follicular B-cell responses to autoantibody pro-
duction in SLE.
A recent report provided evidence for a role of extra-follicular B
helper T-cells in human lupus nephritis [78]. Thus,
CD4+PD1+CXCR3+CXCR5−T-cells, i.e. activated Th1-cells [143] that
produce IL-10 and IFN-γ, were expanded in the blood of SLE patients
and were enriched in the kidney. They induced IgG in an IL-10- and
succinate-dependent manner in vitro, consistent with a pathogenic role.
However, if CXCR5−PD1+Th1-cells are also able to mediate B cell help
in vivo was not investigated. IL-10 producing Th1-cells with similar
characteristics could be induced by IFN-α-producing pDC in vitro, which
may possibly explain their abundance in SLE patients [78]. Notably,
RNA sequencing revealed that these pDC-primed, IL-10 producing Th1-
cells also expressed CCR5, Eomes and Granzymes, suggesting that they
are closely related to Eomes+Tr1-cells [108] (see Review by Hill and
colleague in this special issue). Indeed, Eomes+Tr1-cells have a similar
phenotype [93], and are consequently contained among
CD4+PD1+CXCR3+CXCR5−T-cells (unpublished observation). No-
tably, human extra-follicular B helper T-cells and circulating Th1-cells
can be distinguished from Eomes+Tr1-cells by IL-7R expression
[79,139,143]. Future research should thus clarify if IL-10 and IFN-γ
producing Th1-cells and Tr1-cells have different roles in B-cell re-
sponses and SLE.
We have obtained independent evidence for a pathogenic role of IL-
10 producing, extra-follicular B helper T-cells in SLE. Some time ago we
identified a population of IL-10 producing, auto-reactive CCR6+
memory T-cells [120]. Notably, the “physiological” auto-reactivity in
healthy individuals among helper T-cells is largely confined to
CCR6+T-cells, suggesting that they play a key role in autoimmune
diseases [120]. Consistently, we and others provided evidence for a
pathogenic role of auto-reactive CCR6+T-cells that produce pro-in-
flammatory cytokines in multiple sclerosis [144,145]. Autoreactive
CCR6+ T-cells have a peculiar context-dependent behaviour. They
produce IL-10, but not other cytokines, upon interaction with DC pre-
senting self-MHC. However, they express IL-2 and CD40 L in addition
upon stimulation with recall antigens like tetanus toxoid. Since tetanus
vaccination protects by the induction of neutralising antibodies, we
speculated that CCR6+ memory T-cells might provide help for B-cell in
recall responses [120]. Indeed, we found recently that CCR6+IL-7R+
from human tonsils and from spleens of IL-10 reporter mice induced IgG
in a partially IL-10-dependent manner in vitro and in vivo [45]. IL-10
producing CCR6+T-cells are central memory-like cells that lack BCL6,
as well as IL-17 and IFN-γ producing capacities, indicating that they are
distinct from TFH as well as from Th1 and Th17-cells with B helper
functions [78,87,125]. Importantly, they accumulate systemically in
pristane-induced lupus-like disease [146], and selectively in SLE pa-
tients with anti-dsDNA antibodies. In SLE patients, but not in healthy
individuals, they spontaneously induced IgG including anti-dsDNA an-
tibodies in the absence of exogenous TCR agonists. Moreover, they were
highly abundant in lymph nodes of SLE patients and interacted with B-
cells, but were excluded from germinal centres. These data suggest that
IL-10 producing CCR6+T-cells are a distinct population of extra-folli-
cular B-helper T-cells that are autoreactive and drive the generation of
short-lived autoantibody-producing plasma blasts in SLE [45]
In summary, there is accumulating evidence that besides TFH also
extra-follicular B helper T-cells contribute to the aberrant IL-10 and
Fig. 2. Different roles of IL-10 produced by individual immune cell subsets in the regulation of B-cell responses and in SLE. IL-10 in SLE is produced by
myeloid cells like macrophages (MΦ) as well as by different subsets of the B- and T-cell compartments. The current evidence suggests that IL-10 produced by
macrophages and/or by extra-follicular helper T-cells promotes B-cells to differentiate to immunoglobulin-secreting plasma blasts, that might in addition promote
their own generation by an autocrine IL-10 loop (green arrows). Conversely, recent evidence suggests that IL-10 produced by BCL6-expressing follicular helper T-cells
(TFH) may represent a negative feed-back loop (red line). In addition, there is a regulatory loop between Il-10 producing regulatory B-cells and T-cells that appears to
be disturbed in SLE (dotted red lines): IL-10 produced by regulatory B-cells could induce Tr1-cells, which similar to FOXP3+Tregs lack CD40 L and inhibit B-cell
responses, but are dysfunctional in SLE. IL-10 derived from regulatory T-cells does not directly inhibit B-cell responses, but could be important to maintain the
suppressive functions of FOXP3+ and FOXP3− regulatory T-cells in target tissues (red inhibitory arrow).
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autoantibody production in SLE. This pathway appears to be particular
important for the dynamic induction of pathogenic anti-DNA auto-
antibodies [142].
6. Summary/Outlook
It is increasingly recognised that Interleukin-10, the prototypic anti-
inflammatory cytokine, has a paradoxical pathogenic activity in the
systemic autoimmune disease SLE. It seems likely that the capacity of
IL-10 to stimulate autoantibody production by autoreactive B-cells is
key to its pathogenic role, but other, yet unidentified, pathways may
also contribute. The current evidence suggests that IL-10 is produced by
multiple cellular sources in lupus, and that IL-10 produced by different
immune cells might have different functions that depend on the context
or the microenvironment. In particular, CD4+ T-cells are likely to
contribute importantly to the aberrant IL-10 production in lupus. IL-10
is produced by different subsets of regulatory and follicular, as well as
extra-follicular B helper T-cells, which play different roles in SLE. Since
follicular and extra-follicular B-cell responses are preferentially tar-
geted by different therapeutic strategies [7,147], understanding their
relative contributions in individual SLE patients may hold promise for
personalised therapies with higher efficacies.
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